Labcorp strengthens bioanalytical services in Asia Pacific

Labcorp, based in the US, has announced the expansion of its global offerings and its footprint in the Asia Pacific

(APAC) region with the opening of a new, integrated bioanalytical laboratory in Singapore. The laboratory features new capabilities that enhance the substantial array of bioanalytical services currently offered through

Labcorp Drug Development, allowing the company to meet increased demand from pharmaceutical and biotechnology companies. The integrated bioanalytical laboratory will be co-located with Labcorp’s Central Laboratory Services and Clinical Development and Commercialisation Services segments, bolstering the company’s laboratory network in APAC. By expanding its bioanalytical capabilities in Singapore, Labcorp advances its regulated and nonregulated services and further supports the development of small and large molecule studies. The new, integrated laboratory will also offer Good Laboratory Practice (GLP)- and Good Clinical Practice (GCP)-compliant bioanalysis, liquid chromatography-mass spectrometry and immunochemistry platforms, as well as clinical biomarker analytical services.